Maya reports persistent fatigue and increased thirst over the past six months. Results from the same visit show HbA1c of 7.4%, above the stated laboratory range.
Following review, the clinician recorded a diagnosis of type 2 diabetes and started metformin 500 mg twice daily.
Follow-up · 14 March 2025
Response to treatment
Across three subsequent readings, HbA1c improved to 6.4%. The latest result remains linked to the original laboratory report.
Choose whether to use an anonymised patient profile, whether source files remain after processing, and how reports are shared.
⌑
Encrypted at every boundary.
Records stay protected as they move through n1 and whenever they are stored.
Guarded access and infrastructure.
Identity controls and isolated environments protect the health-data workspace.
Technical safeguards
TLS 1.3 for data in transitTraffic between the browser and n1 is encrypted with TLS 1.3. Database connections must also use TLS.AES-256 for stored dataSource records and uploaded files are encrypted at rest with AES-256.Credentials kept in AWS Secrets ManagerAPI keys and service credentials stay out of the codebase. Services receive them only at runtime.Managed WAF and DDoS protectionIncoming requests pass through managed firewall rules and denial-of-service protection before they reach n1 services.Approved accounts with 2FAAccess to internal tools is limited to approved work accounts. A second factor is required at sign-in.Production kept separateProduction and staging run in separate environments. AI processing uses dedicated production infrastructure.
The record shows an improving metabolic trend in an otherwise stable clinical picture. HbA1c fell from 7.1% to 6.4% across three readings. LDL cholesterol and low-grade inflammation still warrant review, while renal function and the blood count remain reassuring. The priority is to confirm the patient-specific range, reconcile treatment, and preserve the source trail behind each conclusion.
Patient noteCurrent treatment and home readings confirmedMetformin is taken twice daily, and home blood pressure is reported as stable.
HbA1c6.4%Down from 7.1%LDL cholesterol116 mg/dLAbove targeths-CRP1.8 mg/LWatchVitamin D71 nmol/LImproving
!Review the patient-specific rangeAn earlier HbA1c result was above the custom upper limit of 6.8%.
Section 2
Body Systems
MetabolicReview
Glucose control is improving, but the earlier high result supports continued follow-up.
Glucose 5.8 mmol/L
CardiovascularReview
LDL remains above target. Read it with blood pressure, treatment, and family history.
LDL 116hs-CRP 1.8
HepaticStable
Liver markers are within the stated ranges with no source-linked sign of injury.
ALT 28 U/LAST 24 U/L
InflammatoryWatch
Mild inflammation should be re-read after metabolic and clinical review.
hs-CRP 1.8WBC 6.7
RenalStable
Kidney function is preserved. Continue routine monitoring with the full record.
eGFR 91Creatinine 82
HaematologicalStable
Blood counts are in range and provide no current signal for urgent review.
Hb 148 g/LPlatelets 244
NutritionalWatch
Vitamin D is improving. Confirm supplements and repeat against the same range.
Vitamin D 71B12 410
Section 3
Cross-System Patterns
Metabolic control is improving
The HbA1c trend is moving in the right direction, but should remain linked to weight, medicines, and fasting glucose.
Vascular risk extends beyond LDL
LDL, inflammation, blood pressure, and family history should be reviewed as one risk picture.
Inflammation may track metabolic load
The mild hs-CRP result is more useful as a trend than as an isolated finding.
Nutrient status may affect the picture
Vitamin D and supplement use should be confirmed before the next interpretation.
Section 4
Recommendations
Next visit
Review the confirmed metformin plan, custom HbA1c range, supplements, weight, and logged home blood pressure.
2–4 weeks
Review cardiovascular risk with the full lipid profile and decide whether ApoB would change care.
8–12 weeks
Repeat HbA1c and hs-CRP after the agreed plan, using the same units and reference settings.
Before sharing
Edit the draft, Resolve flagged gaps and complete the clinician approval flow.
Section 5
Data Gaps
Missing laboratoriesAtherogenic particle burden
ApoB or LDL particle number may refine the lipid assessment.
Missing diagnosticsHepatic imaging and fibrosis staging
No liver imaging is available if clinical review raises concern.
Missing clinical contextBlood pressure and anthropometrics
Home readings, weight, BMI, and waist are not confirmed.
Missing diagnosticsGlucose tolerance and beta-cell reserve
An OGTT or C-peptide could answer questions left by fasting results.
Missing recordsMedicines, supplements, and family history
Reconcile these before firm treatment conclusions are made.
Send approved reportThe patient will receive this report in their portal.
EPExample patientVerified portal
Example patient · 2 source-linked diagnoses
Diagnoses
◇No patient data yet
Upload records to extract diagnoses, procedures, medicines, and more.
Records17Structured items99Last updatedToday
Recent patient activitySource linked
01Three records processedAll data ready02Health Summary generatedReady to review03One clinical notePrivate to care team
New patient notePrivate to the care teamPatient note saved ✓
